2. Academic Validation
  3. Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4

Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4

  • J Exp Med. 2016 May 30;213(6):1029-46. doi: 10.1084/jem.20151229.
Travis Lear 1,  Alison C McKelvey 2,  Shristi Rajbhandari 2,  Sarah R Dunn 2,  Tiffany A Coon 2,  William Connelly 2,  Joe Y Zhao 2,  Daniel J Kass 3,  Yingze Zhang 3,  Yuan Liu 2,  Bill B Chen 4
Affiliations

Affiliations

  • 1 Department of Environmental and Occupational Health, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261 Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA 15213.
  • 2 Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA 15213.
  • 3 Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA 15213 Simmons Center for Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, PA 15213.
  • 4 Department of Environmental and Occupational Health, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261 Department of Medicine, Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA 15213 Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15213 chenb@upmc.edu.
PMID: 27162139 DOI: 10.1084/jem.20151229
Abstract

The E3 small ubiquitin-like modifier (SUMO) protein Ligase protein inhibitor of activated STAT 4 (PIAS4) is a pivotal protein in regulating the TGFβ pathway. In this study, we discovered a new protein isoform encoded by KIAA0317, termed fibrosis-inducing E3 Ligase 1 (FIEL1), which potently stimulates the TGFβ signaling pathway through the site-specific ubiquitination of PIAS4. FIEL1 targets PIAS4 using a double locking mechanism that is facilitated by the kinases PKCζ and GSK3β. Specifically, PKCζ phosphorylation of PIAS4 and GSK3β phosphorylation of FIEL1 are both essential for the degradation of PIAS4. FIEL1 protein is highly expressed in lung tissues from patients with idiopathic pulmonary fibrosis (IPF), whereas PIAS4 protein levels are significantly reduced. FIEL1 overexpression significantly increases fibrosis in a bleomycin murine model, whereas FIEL1 knockdown attenuates fibrotic conditions. Further, we developed a first-in-class small molecule inhibitor toward FIEL1 that is highly effective in ameliorating fibrosis in mice. This study provides a basis for IPF therapeutic intervention by modulating PIAS4 protein abundance.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-114366
    FIEL1 Inhibitor